Although the mechanism by which SESN3 inactivates the Wnt/β-catenin remains unclear, this study may provide novel insights into the management of LC that EGR1 and miR-675 may serve as potential targets for LC treatment. Here, EGR1 is linked to laryngotracheoesophageal cleft.